Mikania glomerata Spreng. (Asteraceae): its therapeutic use and potential in the COVID-19 pandemic

• Autor(a) principal: Souza, Juliana Oliveira de
• Data de Publicação: 2022
• Outros Autores: Oliveira, Emilly Flores, Santos, Maria Eduarda Spier dos, Kirsten, Camila Nedel
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Fitos
• Texto Completo: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1292
• topic: Mikania glomerata; Guaco; Covid-19; Coronavirus; Treatment; Mikania glomerata; Guaco; Covid-19; Coronavírus; Tratamento

Mikania glomerata Spreng. (Asteraceae), known as Guaco, is widely used in the therapy of respiratory diseases, with an expectorant, antitussive, and bronchodilator action. This species is listed in the National List of Essential Medicines and hence, it can be used in primary health care in the SUS (Universal Health Care). In late 2019 in Wuhan, China, we had the outbreak of a new type of Coronavirus, SARS-Cov-2 (COVID-19), with an accelerated spread, which soon became a worldwide pandemic. There is still no specific therapy to treat the disease. Most of those people infected by the virus present a mild to moderate respiratory disease as a symptom. Therefore, this study constituted a literature review and aimed to evaluate the therapeutic properties of Guaco and its respective use in the COVID-19 pandemic. In total, two hundred and sixty-six articles were found, in the six databases used, in which nine were selected for review purposes due to their content fitness with the theme and goal of this work. It was found that Mikania glomerata, a popular medicinal plant used in the treatment of cough and respiratory problems, can be used as an adjunct in the treatment of COVID-19.